Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?

Int J Infect Dis. 2020 Oct:99:75-76. doi: 10.1016/j.ijid.2020.07.056. Epub 2020 Jul 29.

Authors

Antonella d'Arminio Monforte¹, Alessandro Tavelli², Francesca Bai², Giulia Marchetti², Alessandro Cozzi-Lepri³

Affiliations

¹ Clinic of Infectious Diseases, Department of Health Science, ASST Santi Paolo e Carlo, University of Milan, Italy. Electronic address: antonella.darminio@unimi.it.
² Clinic of Infectious Diseases, Department of Health Science, ASST Santi Paolo e Carlo, University of Milan, Italy.
³ Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Azithromycin
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections* / drug therapy
Dust
Humans
Hydroxychloroquine / therapeutic use
Pandemics*
Pneumonia, Viral*
SARS-CoV-2

Substances

Dust
Hydroxychloroquine
Azithromycin